Skip to main content
Top
Published in: Endocrine 3/2012

Open Access 01-06-2012 | Letter to the Editor

Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life—why patients with inguinal hernia served as controls

Authors: Ewa Matuszczak, Adam Hermanowicz, Wojciech Debek

Published in: Endocrine | Issue 3/2012

Login to get access

Excerpt

In our study “Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life” [1], we measured serum AMH (anti-Mullerian hormone) levels in boys with cryptorchidism and boys with inguinal hernia. AMH is secreted by immature Sertoli cells during the 8th week of gestation, and is responsible for the regression of Mullerian ducts in the male fetus as part of the sexual differentiation process. With the onset of puberty and spermatogenesis in healthy men, the secretion of AMH declines in correlation to the maturation of Sertoli cells. Only Sertoli cells remain active during childhood, so the evaluation of gonadal function in the prepubertal male relies on the assessment of Sertoli cell products [2]. …
Literature
1.
go back to reference E. Matuszczak, A. Hermanowicz, W. Debek et al., Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life. Endocrine (2011) (epub ahead of print) E. Matuszczak, A. Hermanowicz, W. Debek et al., Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life. Endocrine (2011) (epub ahead of print)
2.
go back to reference M.M. Lee, M. Misra, P.K. Donahoe, D.T. MacLaughlin, MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol. Cell. Endocrinol. 211, 91–98 (2003)PubMedCrossRef M.M. Lee, M. Misra, P.K. Donahoe, D.T. MacLaughlin, MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol. Cell. Endocrinol. 211, 91–98 (2003)PubMedCrossRef
3.
go back to reference B. Zendejas, A.E. Zarroug, Y.M. Erben et al., Impact of childhood inguinal hernia repair in adulthood: 50 years of follow-up. J. Am. Coll. Surg. 211, 762–768 (2010)PubMedCrossRef B. Zendejas, A.E. Zarroug, Y.M. Erben et al., Impact of childhood inguinal hernia repair in adulthood: 50 years of follow-up. J. Am. Coll. Surg. 211, 762–768 (2010)PubMedCrossRef
4.
go back to reference D.S. Engeler, P.O. Hosli, H. John, Early orchiopexy: prepubertal intratubular germ cell neoplasia and fertility outcome. Urology 56, 144–148 (2000)PubMedCrossRef D.S. Engeler, P.O. Hosli, H. John, Early orchiopexy: prepubertal intratubular germ cell neoplasia and fertility outcome. Urology 56, 144–148 (2000)PubMedCrossRef
Metadata
Title
Serum AMH concentration as a marker evaluating gonadal function in boys operated on for unilateral cryptorchidism between 1st and 4th year of life—why patients with inguinal hernia served as controls
Authors
Ewa Matuszczak
Adam Hermanowicz
Wojciech Debek
Publication date
01-06-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9602-6

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine